Medline ® Abstract for Reference 6

of 'Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn'

6
TI
Maternal IgG anti-A and anti-B titres predict outcome in ABO-incompatibility in the neonate.
AU
Bakkeheim E, Bergerud U, Schmidt-Melbye AC, Akkök CA, Liestøl K, Fugelseth D, Lindemann R
SO
Acta Paediatr. 2009;98(12):1896.
 
AIM: To evaluate predictors for risk of severe hyperbilirubinaemia and kernicterus in ABO-incompatible neonates with emphasize on maternal IgG anti-A/-B titres.
METHODS: Blood group O women in labour at Oslo University Hospital, Ullevål, were included in the years 2004-2006. Offspring with blood group A or B had direct antiglobulin test performed and IgG anti-A/-B levels measured in maternal plasma. Blood group A or B infants developing severe hyperbilirubinaemia, received in addition to phototherapy, immunoglobulin treatment and/or exchange transfusion (EXT).
RESULTS: Of 253 neonates, 61.3% had blood group O, 29.6% blood group A and 9.1% blood group B. Twenty neonates with blood group A or B received at least one immunoglobulin treatment. In multivariate analysis, maternal antibody-titres were the only significant predictors for immunoglobulin treatment (p<0.0001), EXTs (p<0.05) and duration of phototherapy (p<0.0001). The need for invasive treatment increased sharply for antibody titres>or =512. Receiver operating characteristic analyses demonstrated that titres>or =512 had a sensitivity of 90% and a specificity of 72% for predicting immunoglobulin treatment and thus severe hyperbilirubinaemia.
CONCLUSION: Maternal IgG anti-A/-B titres contribute to the prediction of risk of severe hyperbilirubinaemia in ABO-incompatible neonates, in addition to blood-grouping and direct antiglobulin-testing, especially following early discharge after delivery.
AD
Department of Paediatrics, Oslo University Hospital, Ullevål, Oslo, Norway. egil.bakkeheim@uus.no
PMID